Eric J. Bow

13.2k total citations · 5 hit papers
75 papers, 8.3k citations indexed

About

Eric J. Bow is a scholar working on Oncology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Eric J. Bow has authored 75 papers receiving a total of 8.3k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Oncology, 42 papers in Epidemiology and 35 papers in Infectious Diseases. Recurrent topics in Eric J. Bow's work include Neutropenia and Cancer Infections (48 papers), Antifungal resistance and susceptibility (30 papers) and Fungal Infections and Studies (27 papers). Eric J. Bow is often cited by papers focused on Neutropenia and Cancer Infections (48 papers), Antifungal resistance and susceptibility (30 papers) and Fungal Infections and Studies (27 papers). Eric J. Bow collaborates with scholars based in Canada, United States and France. Eric J. Bow's co-authors include Kenneth V. I. Rolston, John R. Wingard, James I. Ito, Craig A. Mullen, Jo‐Anne H. Young, Michael Boeckh, Alison G. Freifeld, Kent A. Sepkowitz, Issam Raad and Philip A. Pizzo and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Eric J. Bow

75 papers receiving 8.1k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America

2011 2.3k citations Eric J. Bow, Jo‐Anne H. Young et al. Clinical Infectious Diseases profile →
2002 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer

2002 1.4k citations Eric J. Bow et al. Clinical Infectious Diseases profile →
Executive Summary: Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America

2011 507 citations Eric J. Bow, Jo‐Anne H. Young et al. Clinical Infectious Diseases profile →
Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update

2018 356 citations Eric J. Bow et al. Journal of Clinical Oncology profile →
Combination Antifungal Therapy for Invasive Aspergillosis

2015 333 citations Kieren A. Marr, Eric J. Bow et al. profile →

Peers

Countries citing papers authored by Eric J. Bow

Since Specialization

Citations

This map shows the geographic impact of Eric J. Bow's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric J. Bow with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric J. Bow more than expected).

Fields of papers citing papers by Eric J. Bow

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric J. Bow. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric J. Bow. The network helps show where Eric J. Bow may publish in the future.

Co-authorship network of co-authors of Eric J. Bow

This figure shows the co-authorship network connecting the top 25 collaborators of Eric J. Bow. A scholar is included among the top collaborators of Eric J. Bow based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric J. Bow. Eric J. Bow is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Modeling Invasive Aspergillosis Risk for the Application of Prophylaxis Strategies 2024 ·Open Forum Infectious Diseases ·Jo‐Anne H. Young, David R. Andes, Monica I. Ardura, Antonio Arrieta, Eric J. Bow, Pranatharthi Chandrasekar, Sharon C.‐A. Chen, Sarah P. Hammond, Shahid Husain, Sophia Koo, Valéry Lavergne, M. Hong Nguyen, Thomas F. Patterson, Miranda So, George R. Thompson, C. Orla Morrissey, Mindy G. Schuster	12
2	Evaluation of the Impact of the Urgent Cancer Care Clinic on Emergency Department Visits, Primary Care Clinician Visits, and Hospitalizations in Winnipeg, Manitoba 2023 ·Current Oncology ·(unknown), Pascal Lambert, Eric J. Bow, Piotr Czaykowski, (unknown), Benjamin A. Goldenberg, (unknown), Harminder Singh, Oliver Bucher, Kathleen Decker	3
3	Hand Hygiene Compliance at a Canadian provincial cancer centre – the complementary roles of nurse auditor-driven and patient auditor-driven audit processes and impact upon practice in ambulatory cancer care 2020 ·American Journal of Infection Control ·Eric J. Bow, (unknown), David R. Phillips, (unknown), Michele Williams, (unknown), (unknown)	3
4	Fungicidal versus fungistatic therapy of invasive Candida infection in non-neutropenic adults: a meta-analysis 2018 ·Mycology&#58 An International Journal on Fungal Biology ·Anand Kumar, Ryan Zarychanski, Amarnath Pisipati, (unknown), (unknown), Shravan Kethireddy, Eric J. Bow	29
5	Potential Consequences of Essential Drug Shortages in Canada: Brain Abscess due to Nocardia farcinica Associated with Dapsone Prophylaxis for Pneumocystis jirovecii Pneumonia 2013 ·Canadian Journal of Infectious Diseases and Medical Microbiology ·Terence Wuerz, Eric J. Bow, Matthew D. Seftel	5
6	Fluoroquinolones, antimicrobial resistance and neutropenic cancer patients 2011 ·Current Opinion in Infectious Diseases ·Eric J. Bow	91
7	Canadian Clinical Practice Guidelines for Invasive Candidiasis in Adults 2010 ·Canadian Journal of Infectious Diseases and Medical Microbiology ·Eric J. Bow, Gerald A. Evans, Jeff Fuller, Michél Laverdière, Coleman Rotstein, Robert Rennie, Stephen D. Shafran, (unknown), (unknown), Peter Phillips, Donald C. Vinh	43
8	Fungal infection prevention after hematopoietic cell transplantation 2009 ·Bone Marrow Transplantation ·Kieren A. Marr, Eric J. Bow, Tom Chiller, Georg Maschmeyer, Patricia Ribaud, Brahm H. Segal, William J. Steinbach, John R. Wingard, Márcio Nucci	41
9	Neutropenic Fever Syndromes in Patients Undergoing Cytotoxic Therapy for Acute Leukemia and Myelodysplastic Syndromes 2009 ·Seminars in Hematology ·Eric J. Bow	32
10	Of Yeasts and Hyphae: A Hematologist’s Approach to Antifungal Therapy 2006 ·Hematology ·Eric J. Bow	9
11	Effect of Recombinant Human Keratinocyte Growth Factor (rHuKGF) on the Immunopathogenesis of Intestinal Graft-Vs.-Host Disease Induced Without a Preconditioning Regimen 2004 ·Journal of Clinical Immunology ·Cynthia A. Ellison, (unknown), (unknown), Alan R. McIntosh, Sheila Scully, Eric J. Bow, Dimitry M. Danilenko, Kent T. HayGlass, John G. Gartner	26
12	Value of routine procurement of Isolator in addition to BacT/Alert blood cultures in febrile neutropenic patients with acute myeloid leukemia 1998 ·Tariq A. Madani, Amin Kabani, D. J. Hoban, (unknown), Eric J. Bow	1
13	Amphotericin B Lipid Complex for Invasive Fungal Infections: Analysis of Safety and Efficacy in 556 Cases 1998 ·Clinical Infectious Diseases ·Thomas J. Walsh, John W. Hiemenz, Nita L. Seibel, John R. Perfect, Gary Horwith, Lily Lee, Jeffrey L. Silber, Mark J. DiNubile, Annette C. Reboli, Eric J. Bow, John Lister, Elias Anaissie	461
14	Cytotoxic therapy-induced D-xylose malabsorption and invasive infection during remission-induction therapy for acute myeloid leukemia in adults. 1997 ·Journal of Clinical Oncology ·Eric J. Bow, (unknown), Mary Cheang, Tsiporah B. Shore, Morel Rubinger, Brent Schacter	78
15	Therapy of untreated acute myeloid leukemia in the elderly: remission-induction using a non-cytarabine-containing regimen of mitoxantrone plus etoposide. 1996 ·Journal of Clinical Oncology ·Eric J. Bow, Jenny Sutherland, (unknown), G. J. Williams, Jennifer Clinch, Tsiporah B. Shore, Morel Rubinger, Brent Schacter	39
16	Invasive Fungal Disease in Adults Undergoing Remission-Induction Therapy for Acute Myeloid Leukemia: The Pathogenetic Role of the Antileukemic Regimen 1995 ·Clinical Infectious Diseases ·Eric J. Bow, (unknown), Mary Cheang, Brent Schacter	145
17	Reduced Requirement for Antibiotic Therapy Targeting Gram-Negative Organisms in Febrile, Neutropenic Patients with Cancer Who Are Receiving Antibacterial Chemoprophylaxis with Oral Quinolones 1995 ·Clinical Infectious Diseases ·Eric J. Bow, (unknown), David Vaughan	32
18	Detection of acute and treated lesions of hepatosplenic candidiasis: Conparison of dynamic contrast‐enhanced CT and MR Imaging 1992 ·Journal of Magnetic Resonance Imaging ·Richard C. Semelka, J. Patrick Shoenut, Howard M. Greenberg, Eric J. Bow	47
19	Comparison of norfloxacin with cotrimoxazole for infection prophylaxis in acute leukemia 1988 ·The American Journal of Medicine ·Eric J. Bow, (unknown), Thomas Louie	88
20	Coexistence of Double Gammopathy (IgM Kappa and IgM Lambda) in the Serum of a Single Individual with Chronic Lymphocytic Leukemia 1983 ·Acta Haematologica ·(unknown), (unknown), Eric J. Bow	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact